Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F(2α) analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocul...

Descripción completa

Detalles Bibliográficos
Autores principales: Holló, Gábor, Vuorinen, Jouni, Tuominen, Juhani, Huttunen, Teppo, Ropo, Auli, Pfeiffer, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177040/
https://www.ncbi.nlm.nih.gov/pubmed/25213118
http://dx.doi.org/10.1007/s12325-014-0151-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177040/
https://www.ncbi.nlm.nih.gov/pubmed/25213118
http://dx.doi.org/10.1007/s12325-014-0151-7

Ejemplares similares